This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garrigue, I.
Right arrow Articles by Thiébaut, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garrigue, I.
Right arrow Articles by Thiébaut, R.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, February 2008, p. 493-498, Vol. 46, No. 2
0095-1137/08/$08.00+0     doi:10.1128/JCM.01499-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Prediction of Cytomegalovirus (CMV) Plasma Load from Evaluation of CMV Whole-Blood Load in Samples from Renal Transplant Recipients{triangledown}

Isabelle Garrigue,1,2* Adélaïde Doussau,3 Julien Asselineau,3 Hélène Bricout,3 Lionel Couzi,5 Catherine Rio,5 Pierre Merville,5 Hervé Fleury,1,2 Marie-Edith Lafon,1,2 and Rodolphe Thiébaut3,4

Laboratoire de Virologie EA2968 and IFR66, Université Bordeaux 2,1 Laboratoire de Virologie,2 Clinical Epidemiology Unit,3 Unité de Transplantation Rénale, Département de Néphrologie, Centre Hospitalier Universitaire de Bordeaux,5 INSERM U875 Biostatistics and CIE7, F-33 076 Bordeaux, France4

Received 26 July 2007/ Returned for modification 14 September 2007/ Accepted 20 November 2007

In a prospective cohort of 82 renal transplant recipients, we evaluated the capacity of the cytomegalovirus (CMV) load in whole blood (WB) to predict the plasma CMV load, aiming to identify active CMV infections by using WB samples only and to deduce a WB threshold. Using quantitative real-time PCR, a total of 1,474 WB samples were assayed, of which 279 were positive for CMV, and 140 out of the 276 paired plasma samples tested positive. Thirty (36.6%) patients presented with at least one positive plasma PCR result, and 21 infection episodes (19 patients) required curative treatment (median follow-up time, 12 months). When the plasma CMV load was >500 copies/ml (n = 70), more than 94% (95% confidence interval, 86.0%, 98.4%) of WB samples had >500 copies/ml. Two prediction models were built: log10 plasma viral load (VL) was calculated as –0.3777 + 0.9342 x log10 WB VL and as –0.3777 + 0.8563 x log10 WB VL for patients with and without treatment, respectively. In the validation sample (578 routine samples), 77.2% of the observed and expected plasma viral loads were concordant (95% confidence intervals, 73.5 and 80.5%). According to the model, the plasma viral load was >500 copies/ml when the WB load was >3,170 or >4,000 copies/ml in patients with or without treatment, respectively. WB seems to be an appropriate candidate for routine CMV monitoring of transplant recipients by using a single assay.

* Corresponding author. Mailing address: Université Victor Segalen Bordeaux 2, Laboratoire de Virologie EA2968, 146 rue Léo Saignat, 33 076 Bordeaux Cédex, France. Phone: 33 5 57 57 13 63. Fax: 33 5 56 99 11 40. E-mail: isabelle.garrigue{at}chu-bordeaux.fr

{triangledown} Published ahead of print on 5 December 2007.

Journal of Clinical Microbiology, February 2008, p. 493-498, Vol. 46, No. 2
0095-1137/08/$08.00+0     doi:10.1128/JCM.01499-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»